Triple Agonists (GLP-1/GIP/Glucagon) Monitoring Bundle

What Is the Triple Agonist Drug Class?

Triple agonists are a class of single-molecule peptides that simultaneously activate three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Each receptor contributes a distinct and additive metabolic action. GLP-1R activation suppresses appetite and slows gastric emptying. GIPR activation augments insulin secretion in a glucose-dependent manner and may independently reduce fat mass. GCGR activation raises resting energy expenditure and drives hepatic lipid oxidation, effects that single-receptor agents cannot replicate.

Retatrutide (LY3437943, Eli Lilly) is the most clinically advanced prototype. The Phase 2 trial published in the New England Journal of Medicine in 2023 (N=338 participants with obesity) demonstrated mean weight loss of 24.2% at 48 weeks at the 12 mg dose, compared with 2.1% in the placebo arm. No approved triple agonist exists in the United States as of early 2025, but prescribers at academic centers and within clinical trials are already managing these patients.

How Triple Agonism Differs from Dual and Single-Receptor Agents

Semaglutide (GLP-1R only) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [1]. Tirzepatide (GLP-1R plus GIPR) produced up to 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [2]. Retatrutide's Phase 2 signal of 24.2% at 48 weeks suggests the glucagon receptor adds meaningful incremental efficacy, though direct head-to-head trials are pending.

The GCGR component also generates a distinct lipid phenotype. GCGR agonism raises hepatic fatty acid oxidation and reduces intrahepatic triglyceride content, making these agents particularly relevant for metabolic dysfunction-associated steatotic liver disease (MASLD). A 24-week sub-analysis of the retatrutide Phase 2 data showed reductions in liver fat fraction by MRI-PDFF of approximately 81% from baseline in the highest-dose cohort [3].

Agents in This Class (Pipeline Status, 2025)

| Agent | Company | Receptors | Stage | |---|---|---|---| | Retatrutide | Eli Lilly | GLP-1R / GIPR / GCGR | Phase 3 | | Mazdutide | Innovent/Roche | GLP-1R / GCGR | Phase 3 (China) | | IBI362 | Innovent | GLP-1R / GCGR | Phase 2 | | CT-996 | Carmot (Roche) | GLP-1R / GIPR / GCGR | Phase 2 |

Prescribers should confirm current registration status before initiating any of these agents outside a trial.

Baseline Assessment Before Prescribing

Every patient considered for a triple agonist requires a thorough baseline evaluation. The glucagon receptor component introduces hepatic and lipid effects that go beyond what clinicians manage with GLP-1-only agents, so a more detailed metabolic workup is warranted.

Required Baseline Laboratory Panel

Order all of the following before the first dose:

• Complete metabolic panel (CMP): sodium, potassium, CO2, BUN, creatinine, glucose, calcium, total protein, albumin, bilirubin, AST, ALT, alkaline phosphatase.
• Fasting lipid panel: LDL-C, HDL-C, total cholesterol, triglycerides. GCGR agonism may raise HDL-C and lower triglycerides but can also increase LDL-C in some patients.
• HbA1c and fasting plasma glucose: establishes glycemic baseline and screens for undiagnosed type 2 diabetes.
• Amylase and lipase: pancreatitis is a class-level risk for GLP-1-based therapies. The FDA's 2023 communication on GLP-1 receptor agonists [4] notes the signal warrants baseline documentation.
• Thyroid-stimulating hormone (TSH): class-level thyroid C-cell concern, analogous to liraglutide and semaglutide.
• Urine albumin-to-creatinine ratio (UACR) and eGFR: renal function affects dosing and tolerability.
• Hepatic imaging (liver ultrasound or FibroScan): for patients with suspected MASLD, baseline imaging quantifies hepatic fat before therapy. MRI-PDFF is the gold standard when available.

Baseline Vitals and Physical Exam

Record resting heart rate. GLP-1R agonists raise resting heart rate by 1 to 4 beats per minute on average [5]. The glucagon receptor component may amplify this through adrenergic activation. A baseline 12-lead ECG is advisable in patients over age 50 or with known cardiovascular disease.

Body weight, BMI, and waist circumference should be documented precisely. These serve as the efficacy benchmarks against which dose escalation decisions are made.

Contraindication Screening

Screen all patients for:

1. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). These remain class-level contraindications.
2. Active or recent acute pancreatitis or chronic pancreatitis with exocrine insufficiency.
3. Active gallbladder disease. GLP-1-based agents slow gallbladder motility and increase cholelithiasis risk. The SCALE Obesity trial with liraglutide reported a 2.6-fold increase in gallbladder-related events [6].
4. Pregnancy or planned pregnancy within 6 months. No reproductive safety data exist for triple agonists.
5. Severe hepatic impairment (Child-Pugh C). GCGR agonism generates hepatic metabolic effects that have not been studied in decompensated cirrhosis.

Dose Titration Protocol and Safety Monitoring During Up-Titration

Slow titration is the single most effective strategy for reducing gastrointestinal adverse events. Nausea occurred in 42% of participants at the 12 mg retatrutide dose in Phase 2, compared with 10% on placebo [3]. Most events were mild to moderate and resolved within 4 weeks of dose stabilization.

Titration Schedule (Phase 2 Protocol Reference)

The Phase 2 retatrutide titration used the following subcutaneous weekly injection schedule:

| Week | Dose | |---|---| | 1 to 4 | 2 mg once weekly | | 5 to 8 | 4 mg once weekly | | 9 to 12 | 8 mg once weekly | | 13 onward | 12 mg once weekly (maintenance) |

This 12-week ramp is longer than the tirzepatide label (4-week intervals starting at 2.5 mg) and reflects the GCGR component's additional GI and hepatic burden during up-titration.

Clinical judgment may require extending any step by 4 weeks if nausea, vomiting, or transaminase elevation occurs. Do not skip dose levels to accelerate titration. Speed does not improve efficacy endpoints and substantially increases dropout.

Monitoring During Titration

Check the following at each dose-step visit (approximately every 4 weeks during the ramp):

• Body weight: document kg, not just pounds. A 5% reduction from baseline by week 12 is a reasonable early-efficacy target.
• AST and ALT: GCGR agonism increases hepatic fatty acid flux. Transient transaminase elevations of 1.5 to 3 times the upper limit of normal have been reported in Phase 2 data. If ALT exceeds 3 times ULN on two consecutive checks, hold the dose. If ALT exceeds 5 times ULN at any point, discontinue.
• Fasting glucose and, if diabetic, HbA1c: the triple agonist's insulinotropic and glucagonostatic effects may lower glucose sharply, requiring sulfonylurea or insulin dose reduction.
• Amylase and lipase: check at week 4 and week 12 during titration. Lipase elevation of 3 times ULN without abdominal pain does not require discontinuation but warrants closer follow-up.
• Resting heart rate: document at every visit. Sustained resting heart rate above 100 bpm warrants cardiology review.
• Blood pressure: GCGR agonism may lower blood pressure through natriuresis; adjust antihypertensives accordingly.

Steady-State Monitoring (Post-Titration, Maintenance Phase)

Once the patient reaches maintenance dose and has tolerated it for 8 consecutive weeks, monitoring intensity can decrease. The goal shifts from tolerability surveillance to efficacy tracking and long-term safety.

Laboratory Schedule at Steady State

| Test | Frequency | |---|---| | CMP with LFTs | Every 6 months | | Fasting lipid panel | Every 6 months (may shift to annually after 12 months if stable) | | HbA1c | Every 3 months if diabetic; every 6 months if non-diabetic | | TSH | Annually | | UACR / eGFR | Annually | | Amylase / lipase | Only if symptoms arise |

Hepatic Efficacy Monitoring for MASLD

Patients initiating triple agonist therapy for MASLD deserve dedicated hepatic response assessment. Repeat MRI-PDFF or FibroScan at 24 to 26 weeks to quantify fat fraction reduction. A decrease in controlled attenuation parameter (CAP) of at least 30 dB/m is considered a meaningful hepatic response by the American Association for the Study of Liver Diseases [7].

Repeat liver biopsy is not routinely recommended solely for drug-monitoring purposes outside of clinical trial protocols.

Weight Plateau Assessment

At 24 weeks on a stable maintenance dose, apply the HealthRX Triple Agonist Response Framework to triage patients:

1. Adequate responder: weight loss at or above 10% from baseline. Continue current dose. Reassess glycemic and hepatic endpoints.
2. Partial responder: weight loss of 5% to 9.9% from baseline. Review adherence, dietary intake, and concomitant medications (antipsychotics, corticosteroids, or insulin may blunt response). Consider whether dose was truly maximized per protocol.
3. Non-responder: weight loss below 5% from baseline at 24 weeks. Evaluate for secondary causes of obesity resistance (hypothyroidism, Cushing syndrome, polygenic hyperphagia). Discontinuation may be appropriate.

This framework mirrors the structure proposed in the ADA/EASD consensus on obesity pharmacotherapy but is adapted for the longer titration timeline of triple agonists [8].

Adverse Event Surveillance and Management

Gastrointestinal Events

Nausea, vomiting, and diarrhea are the most common adverse events across the GLP-1-based class. In the retatrutide Phase 2 trial, nausea was reported by 42% of participants on 12 mg and 14% on placebo. Vomiting occurred in 20% versus 4% [3].

Management steps:

• Counsel patients to eat smaller portions and avoid high-fat meals during titration.
• Ondansetron 4 mg as-needed is reasonable for breakthrough nausea.
• If vomiting is persistent (more than 3 episodes per day for more than 2 days), hold the next scheduled injection and reassess at a lower dose level.

Hepatotoxicity Risk from GCGR Agonism

The glucagon receptor drives hepatic glycogenolysis and fatty acid oxidation. During the first weeks of therapy, rapid mobilization of intrahepatic lipid can generate transient transaminase elevations. This is distinct from drug-induced liver injury (DILI) and typically resolves without dose reduction in mild cases.

The DILI Network severity criteria define significant hepatotoxicity as ALT at or above 3 times ULN with total bilirubin above 2 times ULN (Hy's Law). No case meeting Hy's Law was reported in available retatrutide Phase 2 data, but prescribers should remain vigilant.

Cardiovascular Monitoring

GLP-1-based therapies have an established cardiovascular benefit signal in patients with type 2 diabetes. The LEADER trial (liraglutide, N=9,340) reported a 13% relative risk reduction in the primary MACE composite [9]. Whether the GCGR component attenuates, preserves, or amplifies this benefit is unknown; the SELECT-equivalent cardiovascular outcomes trial for retatrutide has not yet reported.

Until cardiovascular outcomes data are available, apply standard secondary-prevention lipid and blood pressure targets in high-risk patients rather than assuming the triple agonist confers cardiac protection.

Hypoglycemia Risk Stratification

Triple agonists do not directly stimulate insulin secretion in a glucose-independent manner. GLP-1R and GIPR agonism are glucose-dependent. However, co-administration with sulfonylureas or insulin substantially raises hypoglycemia risk.

The American Diabetes Association 2024 Standards of Care state: "Reduction of insulin or insulin secretagogue doses should be considered when adding GLP-1 receptor agonist therapy to avoid hypoglycemia" [8]. The same principle applies to triple agonists, and the effect may be larger given the broader receptor engagement.

Reduce sulfonylurea dose by 50% at initiation. For patients on basal insulin, a 20% insulin dose reduction at the time of first injection is a reasonable starting point, with subsequent titration based on fasting glucose logs.

Special Populations and Prescribing Considerations

Patients with Type 2 Diabetes

Triple agonists showed statistically significant HbA1c reductions of 2.02 percentage points from baseline at 24 weeks in the retatrutide Phase 2 cohort with type 2 diabetes, compared with 0.49 percentage points for placebo (P<0.001) [3]. This is a larger effect than the 1.5 percentage-point HbA1c reduction seen with semaglutide 2.4 mg in STEP-2 (N=1,210 with type 2 diabetes) [10].

Metformin can be continued without dose adjustment. Reduce or eliminate SGLT2 inhibitors only if volume depletion is a concern.

Patients with MASLD/MASH

This is the population where the GCGR component contributes most uniquely. Hepatic fat reduction of 81% from baseline (MRI-PDFF) at 24 weeks in the highest-dose retatrutide cohort represents a magnitude of hepatic benefit not previously seen with single or dual agonists [3].

Baseline FibroScan to stage fibrosis is recommended. Patients with advanced fibrosis (F3 to F4) need closer LFT monitoring given the potential for rapid fat mobilization to stress already-compromised hepatocytes.

Renal Impairment

No formal renal dose-adjustment recommendations exist for retatrutide as of 2025, as Phase 2 excluded patients with eGFR below 30 mL/min/1.73 m2. Use with caution in patients with eGFR 30 to 60, and monitor renal function every 3 months during titration given the risk of dehydration from GI adverse events.

Older Adults (Age 65 and Above)

Start at the lowest dose and extend each titration step to 8 weeks rather than 4. Sarcopenia is a concern with any therapy producing greater than 15% body weight loss. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that "preservation of lean mass requires resistance exercise training concurrent with pharmacotherapy-induced weight loss" [11].

Order DEXA scan at baseline and at 12 months in patients age 65 and above to track lean mass alongside fat mass.

Drug Interactions Relevant to This Class

| Interacting Drug | Mechanism | Clinical Action | |---|---|---| | Sulfonylureas | Additive insulin secretion; risk of hypoglycemia | Reduce sulfonylurea dose by 50% at initiation | | Basal insulin | Additive glucose lowering | Reduce insulin dose by 20% at initiation | | Oral contraceptives | Delayed gastric absorption (first 4 weeks of titration) | Use backup contraception for first 4 weeks | | Warfarin | Altered absorption kinetics; INR variability | Monitor INR weekly for first month | | Cyclosporine | Reduced oral bioavailability with delayed gastric emptying | Monitor cyclosporine trough levels closely |

These interactions are extrapolated from the GLP-1 class. Triple-agonist-specific interaction data are limited to Phase 2 safety databases, which did not formally characterize PK interactions.

Discontinuation Criteria

Stop the triple agonist immediately if any of the following occur:

• Confirmed acute pancreatitis (lipase above 3 times ULN with acute abdominal pain and imaging confirmation).
• ALT above 5 times ULN on a single measurement, or above 3 times ULN on two consecutive measurements 2 or more weeks apart.
• Sustained resting heart rate above 110 bpm without identifiable reversible cause.
• Calcitonin level above 50 pg/mL on repeat testing, which warrants thyroid ultrasound and endocrinology referral per MTC risk protocols.
• Pregnancy confirmed. Animal reproductive toxicity studies with GLP-1-based agents show fetal growth restriction at supratherapeutic doses [4].
• Patient-reported severe or persistent vomiting resulting in documented weight loss of more than 3% of body weight within 2 weeks (suggests caloric deficit from GI intolerance rather than pharmacologic appetite suppression).

Summary Monitoring Timeline

| Timepoint | Action | |---|---| | Baseline (pre-dose) | CMP, LFTs, lipid panel, HbA1c, FPG, amylase/lipase, TSH, UACR, ECG, weight, BMI, waist circumference, hepatic imaging if MASLD | | Week 4 (2 mg to 4 mg) | Weight, LFTs, fasting glucose, HR, BP, GI symptom review | | Week 8 (4 mg to 8 mg) | Weight, LFTs, fasting glucose, HR, amylase/lipase, GI symptom review | | Week 12 (8 mg to 12 mg) | Full CMP, lipid panel, LFTs, HbA1c, HR, BP, weight | | Week 24 (maintenance) | Full panel as above plus hepatic imaging (MASLD patients), apply response framework | | Every 6 months thereafter | CMP with LFTs, lipid panel, HbA1c (diabetic patients), weight, BP, HR | | Annually | TSH, UACR/eGFR, DEXA (age 65 and above), lipid panel (if stable) |